Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis

Table e-1 - Overview of study designs Table e-2 - Patients with AEs leading to treatment discontinuation in the OCR all-exposure populationa Table e-3 - Patients with clinically relevant abnormalities in laboratory values in the phase 3 studies Table e-4 - NK cell counts during the CTP of the phase 3 studies Table e-5 - Details of confirmed PML cases outside the clinical trials setting Table e-6 - Description of serious infections associated with IgG levels < LLN Table e-7 - Details of breast cancer cases reported in the OCR all-exposure population Figure e-1 - Change in CD4+ and CD8+ T cell levels in OPERA and ORATORIO Figure e-2 - Change in serum IgA and IgM levels in OPERA and ORATORIO